Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 8/20 | 0.55 |
| ▸ | ACE | P12821 | 7/20 | 0.53 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | ELANE | P08246 | 1/20 | 0.49 |
| ▸ | CTSG | P08311 | 1/20 | 0.49 |
| ▸ | DPP3 | Q9NY33 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11271096 | 1.00 | CMA1 (0.55) | CMA1ACEACE2SLC6A2ELANE | |
| SCHEMBL683120 | 0.93 | SLC6A2 (0.52) | CMA1ACESLC6A2 | |
| SCHEMBL11276961 | 0.91 | CMA1 (0.54) | CMA1ACEACE2 | |
| SCHEMBL683525 | 0.91 | CMA1 (0.48) | CMA1ACEACE2SLC6A2 | |
| Alacepril SCHEMBL11460465 | 0.90 | ACE (0.55) | CMA1ACEACE2SLC6A2DPP3 | |
| Alacepril SCHEMBL5058556 | 0.90 | ACE (0.55) | CMA1ACEACE2SLC6A2DPP3 | |
| Alacepril SCHEMBL34559 | 0.90 | ACE (0.55) | CMA1ACEACE2SLC6A2DPP3 | |
| Alacepril SCHEMBL3204613 | 0.90 | ACE (0.55) | CMA1ACEACE2SLC6A2DPP3 | |
| Alacepril SCHEMBL677447 | 0.90 | ACE (0.55) | CMA1ACEACE2SLC6A2DPP3 | |
| Alacepril SCHEMBL683027 | 0.90 | ACE (0.55) | CMA1ACEACE2SLC6A2DPP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | GAP43, GABRB1, GABRB3 | CMA1 4710/4885ACE 4514/4885ACE2 4392/4885 |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | CMA1 593/4885ACE 6/4885ACE2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.